What Is CJC-1295?
CJC-1295 is a synthetic 30-amino-acid analog of Growth Hormone Releasing Hormone (GHRH residues 1-29) with a modification at the 2nd, 8th, 15th, and 27th amino acid positions. It was developed by ConjuChem Biotechnologies. The "DAC" variant (Drug Affinity Complex) is designed to bind to serum albumin for extended half-life.
Mechanism of Action
CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural pulsatile release of growth hormone. Unlike exogenous GH, it works through the body's own regulatory feedback loop. The DAC modification extends its half-life from minutes (native GHRH) to approximately 6-8 days.
Research Context
- Original Phase 2 clinical trial data from ConjuChem showed sustained GH elevation
- Clinical development was discontinued after a study subject death (unrelated per investigators)
- CJC-1295 without DAC (mod GRF 1-29) is used as a research tool in in-vitro GHRH receptor binding studies
Cited Sources
- According to Teichman, S.L. et al. (2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." JCEM, 91(3), 799-805. [PubMed]
- According to Alba, M. et al. (2006). "Once-daily administration of CJC-1295 maintains GH levels." JCEM, 91(5), 1575-1581. [PubMed]